Smith & Nephew plc (NYSE:SNN) Position Boosted by Clark Estates Inc. NY

Clark Estates Inc. NY grew its stake in shares of Smith & Nephew plc (NYSE:SNN - Free Report) by 16.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 800,000 shares of the medical equipment provider's stock after purchasing an additional 115,000 shares during the period. Smith & Nephew makes up 3.8% of Clark Estates Inc. NY's investment portfolio, making the stock its 5th biggest holding. Clark Estates Inc. NY owned about 0.18% of Smith & Nephew worth $19,664,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in SNN. International Assets Investment Management LLC acquired a new stake in shares of Smith & Nephew in the 3rd quarter worth about $792,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Smith & Nephew by 29.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 27,199 shares of the medical equipment provider's stock worth $847,000 after acquiring an additional 6,164 shares during the last quarter. Stifel Financial Corp acquired a new stake in shares of Smith & Nephew in the 3rd quarter worth about $1,258,000. Maverick Capital Ltd. acquired a new stake in shares of Smith & Nephew in the 3rd quarter worth about $2,086,000. Finally, Blue Trust Inc. raised its holdings in shares of Smith & Nephew by 26.0% in the 4th quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider's stock worth $144,000 after acquiring an additional 1,213 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company's stock.

Remove Ads

Smith & Nephew Price Performance

NYSE SNN traded up $0.35 on Friday, hitting $29.87. The stock had a trading volume of 627,390 shares, compared to its average volume of 788,116. Smith & Nephew plc has a 52-week low of $23.65 and a 52-week high of $31.72. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The company has a market capitalization of $13.06 billion, a price-to-earnings ratio of 13.83, a price-to-earnings-growth ratio of 1.26 and a beta of 0.83. The firm has a 50-day moving average of $25.89 and a 200-day moving average of $27.23.

Smith & Nephew Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Friday, March 28th will be paid a $0.447 dividend. The ex-dividend date of this dividend is Friday, March 28th. This is a boost from Smith & Nephew's previous semi-annual dividend of $0.29. This represents a yield of 2.5%. Smith & Nephew's dividend payout ratio is currently 41.20%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on SNN shares. Canaccord Genuity Group reaffirmed a "hold" rating and issued a $27.00 price objective on shares of Smith & Nephew in a research report on Wednesday, February 26th. StockNews.com raised shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $27.00.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.